BioScrip Inc (NASDAQ:BIOS) has received a consensus rating of “Buy” from the six brokerages that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $3.58.

Several equities research analysts have weighed in on the company. Barrington Research reiterated a “buy” rating and issued a $4.00 price objective on shares of BioScrip in a report on Wednesday, August 8th. Zacks Investment Research cut BioScrip from a “buy” rating to a “hold” rating in a report on Monday, August 6th. Finally, BidaskClub cut BioScrip from a “strong-buy” rating to a “buy” rating in a report on Wednesday, August 1st.

NASDAQ BIOS opened at $2.87 on Wednesday. BioScrip has a fifty-two week low of $1.80 and a fifty-two week high of $3.26. The company has a debt-to-equity ratio of -4.21, a current ratio of 1.91 and a quick ratio of 1.60. The company has a market capitalization of $371.33 million, a price-to-earnings ratio of -6.52 and a beta of -0.04.

BioScrip (NASDAQ:BIOS) last released its quarterly earnings data on Tuesday, August 7th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.04). The business had revenue of $175.79 million during the quarter, compared to analyst estimates of $169.00 million. research analysts expect that BioScrip will post -0.33 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Metropolitan Life Insurance Co. NY lifted its stake in shares of BioScrip by 77.3% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 45,013 shares of the company’s stock valued at $132,000 after purchasing an additional 19,625 shares during the period. MetLife Investment Advisors LLC lifted its stake in shares of BioScrip by 220.8% in the 2nd quarter. MetLife Investment Advisors LLC now owns 64,727 shares of the company’s stock valued at $190,000 after purchasing an additional 44,548 shares during the period. United Services Automobile Association lifted its stake in shares of BioScrip by 441.2% in the 2nd quarter. United Services Automobile Association now owns 109,628 shares of the company’s stock valued at $5,776,000 after purchasing an additional 89,372 shares during the period. Mesirow Financial Investment Management Inc. lifted its stake in shares of BioScrip by 24.3% in the 2nd quarter. Mesirow Financial Investment Management Inc. now owns 114,541 shares of the company’s stock valued at $336,000 after purchasing an additional 22,382 shares during the period. Finally, Sei Investments Co. lifted its stake in shares of BioScrip by 1,826.1% in the 2nd quarter. Sei Investments Co. now owns 124,024 shares of the company’s stock valued at $363,000 after purchasing an additional 117,585 shares during the period. Institutional investors own 84.88% of the company’s stock.

BioScrip Company Profile

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

Featured Article: Hedge Funds Explained

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.